2.1. Subject Selection
chronic kidney disease, diabetes, cardiovascular disease
AUTOIMMUNE HEPATITIS, DRUG-INDUCED LIVER DISEASE, CHRONIC VIRAL HEPATITIS
Participants were recruited from the University of Illinois Chicago Medical Center. The trial was conducted between January 2020 and March 2022. Subjects were enrolled in four separate rounds (~20 subjects per round). Adults between the ages of 18 and 65 years with a BMI between 30 and 60 kg/mExclusion criteria were as follows: history of acute or chronic viral hepatitis, autoimmune hepatitis, or drug-induced liver diseases; alcohol consumption greater than 5 alcoholic drinks per week for women and greater than 10 drinks per week for men in the past 6 months; history of diabetes, cardiovascular disease, or chronic kidney disease; weight instability, i.e., more than 4% weight loss/gain in the past 3 months; or a medical condition or injury that would prevent participation in the aerobic training. The protocol was approved by the Office for the Protection of Research Subjects at the University of Illinois at Chicago, and informed consent was obtained from all participants (IRB #2019-0300). This trial was registered at 